Check-Cap
48 articles with Check-Cap
-
Check-Cap Reports Third Quarter 2020 Financial Results and Corporate Highlights
11/18/2020
Submitted Investigational Device Exemption (IDE) application to the FDA for Pivotal Study of C-Scan®
-
Check-Cap Reports Second Quarter 2020 Financial Results and Corporate Highlights
8/6/2020
IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021.
-
Check-Cap Announces Exercise of Warrants For $9.6 Million Gross Proceeds
7/23/2020
Check-Cap Ltd. announced that it has entered into a definitive agreement with several existing institutional investors for the exercise of certain outstanding warrants to purchase up to an aggregate of 16,054,223 of its ordinary shares at a reduced exercise price of $0.60 per share.
-
Check-Cap Announces Receipt of Nasdaq Minimum Bid Price Notification
6/5/2020
Check-Cap Ltd . (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-Scan ® , the first and only preparation-free ingestible capsule for the prevention of colorectal cancer through the detection of precancerous polyps, today announced that the Company received a let
-
Check-Cap Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/27/2020
Strengthened balance sheet through a total of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020
-
Check-Cap Ltd. Announces $3.0 Million Registered Direct Offering
5/9/2020
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 5,000,000 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
-
Check-Cap Ltd. Announces $4.5 Million Registered Direct Offering
4/30/2020
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,500,001 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
-
Check-Cap Ltd. Announces $4.0 Million Registered Direct Offering
4/20/2020
Check-Cap Ltd. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 6,666,669 of the Company's ordinary shares, at a purchase price of $0.60 per share, in a registered direct offering.
-
Check-Cap Provides Update on COVID-19 Pandemic Impact on Operational and Clinical Activities
4/6/2020
Check-Cap Ltd. provided an update on the impact of the global COVID-19 coronavirus pandemic on the Company's operational and clinical activities.
-
BioSpace Global Roundup, Jan. 2
1/2/2020
Companies from across the globe announce updates to their business and pipeline. -
Check-Cap Announces Positive Results from U.S. Pilot Study of C-Scan® System
12/30/2019
Advancing towards IDE submission to the FDA, targeting initiation of U.S. pivotal study in late 2020
-
Check-Cap Reports Third Quarter 2019 Financial Results and Corporate Highlights
11/6/2019
Successfully launched U.S. pilot study and reported positive final results from post-CE approval study of the C-Scan® System
-
Check-Cap to Present at the Dawson James 5th Annual Small Cap Growth Conference
10/24/2019
Check-Cap Ltd. announced that Alex Ovadia, Chief Executive Officer, will provide a corporate overview at the Dawson James 5th Annual Small Cap Growth Conference, being held October 28-29, 2019 at the Wyndham Grand Hotel in Jupiter, Florida.
-
BioSpace Movers & Shakers, Sept. 27
9/27/2019
Biotech and pharma companies strengthen their leadership teams and boards of directors with this week's appointments. -
Check-Cap to Present at the H.C. Wainwright 21st Annual Global Investment Conference
9/3/2019
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), announced today that Alex Ovadia, Chief Executive Officer, will provide a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference, being held September 8-10, 2019 in New York.
-
BioSpace Global Roundup, Aug. 22
8/22/2019
Companies from across the globe provide updates on their business and pipelines. -
Check-Cap and GE Healthcare Announce Completion of Manufacturing Line Transfer Implementation and Qualification for the C-Scan® System Operated by GE Healthcare
8/19/2019
GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S.
-
BioSpace Global Roundup, July 11
7/11/2019
Companies from across Europe, Asia and around the globe share pipeline and business updates. -
Check-Cap Announces Positive Final Results from Its Post-CE Approval Study of the C-Scan® System
7/9/2019
Check-Cap Ltd., announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system.
-
BioSpace Movers and Shakers, June 7
6/7/2019
Pharma and biotech companies strengthen their executive and leadership teams with new appointments.